TRPM8 antagonist 3

CAS No. 2102179-29-1

TRPM8 antagonist 3( —— )

Catalog No. M28848 CAS No. 2102179-29-1

TRPM8 antagonist 3 is a blocker of TRPM8 (IC50 = 11 nM).

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
5MG 205 Get Quote
10MG 320 Get Quote
25MG 531 Get Quote
50MG 773 Get Quote
100MG 1062 Get Quote
200MG Get Quote Get Quote
500MG Get Quote Get Quote
1G Get Quote Get Quote

Biological Information

  • Product Name
    TRPM8 antagonist 3
  • Note
    Research use only, not for human use.
  • Brief Description
    TRPM8 antagonist 3 is a blocker of TRPM8 (IC50 = 11 nM).
  • Description
    TRPM8 antagonist 3 is a blocker of TRPM8 (IC50 = 11 nM).
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    ——
  • Pathway
    Membrane Transporter/Ion Channel
  • Target
    TRP/TRPV Channel
  • Recptor
    D3 receptor
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    2102179-29-1
  • Formula Weight
    292.315
  • Molecular Formula
    C13H12N2O4S
  • Purity
    >98% (HPLC)
  • Solubility
    In Vitro:?DMSO : 25 mg/mL (85.53 mM)
  • SMILES
    O=C(C1=C(O)N=C(C2=CC=CC=C2O)S1)N3OCCC3
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1.Grundt P, et al. Novel heterocyclic trans olefin analogues of N-{4-[4-(2,3-dichlorophenyl)piperazin-1-yl]butyl}arylcarboxamides as selective probes with high affinity for the dopamine D3 receptor. J Med Chem. 2005 Feb 10;48(3):839-48.
molnova catalog
related products
  • HhAntag

    HhAntag is a small molecule inhibitor of GLI1-mediated transcription, an essential down-stream element of the Hedgehog (Hh) pathway with the anti-tumor activity.

  • GSK2193874

    GSK2193874 was identified as a selective orally active TRPV4 blocker.

  • K 0859

    BGG463 can inhibit c-ABL-T334I, BCR-ABL and BCR-ABL-T315I variants with a 50% inhibitory concentration (IC50) of 0.25 μM, 0.09 μM and 0.590 μM, respectively.